Combining Organoid Models with Next-Generation Sequencing to Reveal Tumor Heterogeneity and Predict Therapeutic Response in Breast Cancer

Figure 6

A potential integrated strategy for precision medicine of breast cancer treatment. Combined with next-generation sequencing, medication sensitivity might be directly evaluated using dose-response experiments on PDOs. In addition, both PDOs and tumors might be utilized to investigate the heterogeneity of tumors and assess the efficacy of target therapy.